Avidity Biosciences, Inc.
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.43%688.872.6%$679.29m
MRNAModerna, Inc. 0.15%118.250.0%$616.94m
AMGNAmgen, Inc. -1.32%225.401.4%$605.62m
BIIBBiogen, Inc. 1.03%267.001.8%$554.62m
GILDGilead Sciences, Inc. -2.19%61.691.0%$514.54m
VRTXVertex Pharmaceuticals, Inc. -1.11%289.541.9%$401.56m
ILMNIllumina, Inc. -1.56%190.793.2%$338.76m
SNSSSunesis Pharmaceuticals, Inc. 4.40%4.270.7%$298.49m
SAVACassava Sciences, Inc. -2.90%41.820.0%$189.63m
BNTXBioNTech SE 0.96%134.880.0%$112.19m
NVAXNovavax, Inc. -1.99%18.2075.6%$84.03m
BMRNBioMarin Pharmaceutical, Inc. -0.34%84.774.2%$82.56m
NRBONeuroBo Pharmaceuticals, Inc. 9.35%13.690.0%$78.90m
PRTAProthena Corp. Plc 1.95%60.6313.8%$78.20m
CRSPCRISPR Therapeutics AG 1.33%65.350.6%$76.10m

Company Profile

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.